Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 4.550
Filter
1.
Zhonghua Zhong Liu Za Zhi ; 46(5): 449-456, 2024 May 23.
Article in Chinese | MEDLINE | ID: mdl-38742358

ABSTRACT

Objectives: To investigate the proportion of different histological types and CT enhanced imaging features of primary middle mediastinal lesions in order to improve the understanding of these tumors and the accuracy of preoperative diagnosis. Methods: Retrospective analysis was conducted on 84 patients with primary middle mediastinal lesions and clear histological classifications diagnosed and treated at the Cancer Hospital, Chinese Academy of Medical Sciences from January 2012 to December 2022. Clinical, imaging, and pathological data were collected and classified according to tumor histological classifications. CT imaging manifestations such as tumor location, size, morphology, edge, boundary, internal components, enhancement characteristics, and surrounding tissue invasion were evaluated and recorded. Results: The histological types of the primary middle mediastinal lesions from the 84 patients included mesenchymal tumors, anterior intestinal cysts, giant lymph node hyperplasia, substernal goiter, neuroendocrine carcinoma, lymphohematopoietic system tumors, and mesothelioma, accounting for 28.6%, 27.4%, 14.3%, 3.6%, 11.9%, 9.5%, and 4.8%, respectively. Mesenchymal tumors included peripheral nerve sheath tumors, vascular tumors, adipogenic tumors, solitary fibrous tumors, and synovial sarcoma, accounting for 54.2%, 20.8%, 12.5%, 8.3%, and 4.2%, respectively. The above tumors had diverse imaging manifestations and specific imaging features. Mature fat were found in 3 cases of liposarcoma; Calcification was observed in 2 cases of thyroid nodules and 7 cases of giant lymph node hyperplasia; Enhanced scanning showed significant enhancement in 2 cases of solitary fibrous tumors, 3 cases of thyroid nodules, and 11 cases of giant lymph node hyperplasia; Mediastinal large lymph nodes was observed in 6 cases of lymphoma and 3 cases of mesothelioma; High invasiveness was observed in 4 cases of mesothelioma and 9 cases of neuroendocrine carcinoma. Conclusion: Mediastinal tumors have low incidence rate and rich histological types, and their imaging manifestations are diverse. Preoperative differential diagnosis can be made according to their specific imaging characteristics.


Subject(s)
Mediastinal Neoplasms , Tomography, X-Ray Computed , Humans , Mediastinal Neoplasms/diagnostic imaging , Mediastinal Neoplasms/pathology , Retrospective Studies , Carcinoma, Neuroendocrine/diagnostic imaging , Carcinoma, Neuroendocrine/pathology , Carcinoma, Neuroendocrine/diagnosis , Lymph Nodes/pathology , Lymph Nodes/diagnostic imaging , Mediastinum/diagnostic imaging , Sarcoma, Synovial/diagnostic imaging , Sarcoma, Synovial/pathology , Sarcoma, Synovial/diagnosis , Middle Aged , Male , Female
2.
J Exp Clin Cancer Res ; 43(1): 148, 2024 May 22.
Article in English | MEDLINE | ID: mdl-38773631

ABSTRACT

BACKGROUND: Primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (cHL) are distinct hematological malignancies of B-cell origin that share many biological, molecular, and clinical characteristics. In particular, the JAK/STAT signaling pathway is a driver of tumor development due to multiple recurrent mutations, particularly in STAT6. Furthermore, the XPO1 gene that encodes exportin 1 (XPO1) shows a frequent point mutation (E571K) resulting in an altered export of hundreds of cargo proteins, which may impact the success of future therapies in PMBL and cHL. Therefore, targeted therapies have been envisioned for these signaling pathways and mutations. METHODS: To identify novel molecular targets that could overcome the treatment resistance that occurs in PMBL and cHL patients, we have explored the efficacy of a first-in-class HSP110 inhibitor (iHSP110-33) alone and in combination with selinexor, a XPO1 specific inhibitor, both in vitro and in vivo. RESULTS: We show that iHSP110-33 decreased the survival of several PMBL and cHL cell lines and the size of tumor xenografts. We demonstrate that HSP110 is a cargo of XPO1wt as well as of XPO1E571K. Using immunoprecipitation, proximity ligation, thermophoresis and kinase assays, we showed that HSP110 directly interacts with STAT6 and favors its phosphorylation. The combination of iHSP110-33 and selinexor induces a synergistic reduction of STAT6 phosphorylation and of lymphoma cell growth in vitro and in vivo. In biopsies from PMBL patients, we show a correlation between HSP110 and STAT6 phosphorylation levels. CONCLUSIONS: These findings suggest that HSP110 could be proposed as a novel target in PMBL and cHL therapy.


Subject(s)
Exportin 1 Protein , Hodgkin Disease , Karyopherins , Receptors, Cytoplasmic and Nuclear , Humans , Karyopherins/antagonists & inhibitors , Karyopherins/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Receptors, Cytoplasmic and Nuclear/antagonists & inhibitors , Animals , Mice , Hodgkin Disease/drug therapy , Hodgkin Disease/pathology , Hodgkin Disease/metabolism , Hodgkin Disease/genetics , Lymphoma, B-Cell/drug therapy , Lymphoma, B-Cell/metabolism , Lymphoma, B-Cell/pathology , Lymphoma, B-Cell/genetics , HSP110 Heat-Shock Proteins/metabolism , HSP110 Heat-Shock Proteins/genetics , Cell Line, Tumor , Mediastinal Neoplasms/drug therapy , Mediastinal Neoplasms/metabolism , Mediastinal Neoplasms/pathology , Mediastinal Neoplasms/genetics , Xenograft Model Antitumor Assays , Triazoles/pharmacology , Triazoles/therapeutic use , Hydrazines/pharmacology , Hydrazines/therapeutic use , Female , STAT6 Transcription Factor/metabolism , Molecular Targeted Therapy
3.
Surg Pathol Clin ; 17(2): 243-255, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38692808

ABSTRACT

Primary sarcoma of the lung and mediastinum is rare. The diagnosis requires careful exclusion of sarcomatoid carcinoma, sarcomatoid mesothelioma, and metastases from extra-thoracic sites. This review summarizes the key morphologic, immunohistochemical, and molecular characteristics of sarcomas that are encountered in the lung and mediastinum. The tumor types discussed are synovial sarcoma, well-differentiated/dedifferentiated liposarcoma, myxoid pleomorphic liposarcoma, intimal sarcoma of the pulmonary artery, inflammatory myofibroblastic tumor, epithelioid hemangioendothelioma, primary pulmonary myxoid sarcoma, malignant peripheral nerve sheath tumor, Ewing sarcoma, and CIC-rearranged sarcoma. Relevant differential diagnoses are also addressed.


Subject(s)
Lung Neoplasms , Mediastinal Neoplasms , Sarcoma , Humans , Mediastinal Neoplasms/pathology , Mediastinal Neoplasms/diagnosis , Lung Neoplasms/pathology , Lung Neoplasms/diagnosis , Sarcoma/pathology , Sarcoma/diagnosis , Diagnosis, Differential , Biomarkers, Tumor
4.
Medicine (Baltimore) ; 103(14): e37704, 2024 Apr 05.
Article in English | MEDLINE | ID: mdl-38579068

ABSTRACT

BACKGROUND: Posterior mediastinal leiomyosarcoma is an extremely rare malignant mesenchymal tumor with no special clinical symptoms, which is easily confused with some common tumors in the posterior mediastinum, affecting the accuracy of the first diagnosis by clinicians and delaying the treatment of patients. CASE SUMMARY: We report a 59-year-old woman with a space-occupying lesion in the posterior mediastinum. The patient was mistakenly diagnosed with lumbar muscle or vertebral body lesions due to chest and back pain and underwent conservative treatment, but her symptoms did not improve significantly and she gradually developed pain in both lower limbs. Chest computed tomography (CT) scan indicated the left lower lung paraspinal space and underwent standard single-aperture video-assisted thoracoscopic surgery (VATS), which was pathologically confirmed as posterior mediastinal leiomyosarcoma. CONCLUSION: Complete surgical resection of posterior mediastinal leiomyosarcoma can achieve good clinical results.


Subject(s)
Leiomyosarcoma , Mediastinal Neoplasms , Humans , Female , Middle Aged , Mediastinum/pathology , Leiomyosarcoma/diagnosis , Leiomyosarcoma/surgery , Leiomyosarcoma/pathology , Mediastinal Neoplasms/diagnosis , Mediastinal Neoplasms/surgery , Mediastinal Neoplasms/pathology , Thorax/pathology , Tomography, X-Ray Computed/methods
5.
Medicina (B Aires) ; 84(2): 324-328, 2024.
Article in Spanish | MEDLINE | ID: mdl-38683517

ABSTRACT

Melanotic schwannoma (MS) is a rare and infrequent subtype of schwannoma characterized by cytoplasmic deposits of melanosomes (melanin). Unlike the other schwannomas, it could have malignant transformation. Due to distinctive characteristics and atypical behavior from classic schwannomas subtypes, MS were renamed and reclassified as "melanocytic malignant neural sheath tumor" in the 5th ed. of the World Health Organization's classification of central nervous system tumors in 2021. We present two cases of MS that underwent complete surgical resection.


El schwannoma melanótico (SM) es una variante rara e infrecuente caracterizada por el depósito citoplasmático de melanosomas (melanina). A diferencia de las otras variantes de schwannomas, tienen capacidad de malignización. Por poseer características y comportamiento distintos al resto de los schwannomas, fue reclasificado como "tumor maligno melanocítico de la vaina neural" en la 5ta edición de la clasificación de los tumores del sistema nervioso central de la Organización Mundial de la Salud en 2021. Presentamos dos casos de SM de ubicación mediastinal en los que se realizó una resección quirúrgica completa.


Subject(s)
Mediastinal Neoplasms , Neurilemmoma , Humans , Neurilemmoma/pathology , Neurilemmoma/diagnostic imaging , Neurilemmoma/surgery , Mediastinal Neoplasms/pathology , Mediastinal Neoplasms/diagnostic imaging , Male , Female , Middle Aged , Adult , Nerve Sheath Neoplasms/pathology , Nerve Sheath Neoplasms/surgery , Nerve Sheath Neoplasms/diagnostic imaging
6.
Cancer Rep (Hoboken) ; 7(4): e2033, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38600050

ABSTRACT

BACKGROUND: Primary cardiac myxofibrosarcoma is a rare and aggressive malignancy, with the majority of approaching strategies relying on case reports. This article provides insights into its diagnosis and treatment. CASE PRESENTATION: This paper presents the case of a 40-year-old man with sudden onset hemoptysis, leading to the diagnosis of primary cardiac myxofibrosarcoma. Treatment involved open-heart surgery to excise the left atrium tumor, followed by 6 cycles of adjuvant chemotherapy. Unfortunately, brain metastasis developed, leading to the patient's death 1 year after initial diagnosis. CONCLUSION: Primary cardiac myxofibrosarcoma remains a clinical challenge with an unfavorable prognosis. Early diagnosis through advanced imaging is crucial, and research is needed to explore innovative treatments. This case underscores the complexities of managing this rare cardiac malignancy and highlights the necessity for ongoing investigations to enhance patient outcomes.


Subject(s)
Fibrosarcoma , Heart Neoplasms , Mediastinal Neoplasms , Male , Adult , Humans , Heart Neoplasms/diagnosis , Heart Neoplasms/surgery , Heart Neoplasms/pathology , Heart Atria/diagnostic imaging , Heart Atria/surgery , Heart Atria/pathology , Prognosis , Fibrosarcoma/diagnosis , Fibrosarcoma/surgery , Mediastinal Neoplasms/pathology
7.
Lung Cancer ; 191: 107558, 2024 May.
Article in English | MEDLINE | ID: mdl-38569278

ABSTRACT

OBJECTIVES: Mediastinal neoplasms are typical but uncommon thoracic diseases with increasing incidence and unfavorable prognoses. A comprehensive understanding of their spatiotemporal distribution is essential for accurate diagnosis and timely treatment. However, previous studies are limited in scale and data coverage. Therefore, this study aims to elucidate the distribution of mediastinal lesions, offering valuable insights into this disease. MATERIALS AND METHODS: This multi-center, hospital-based observational study included 20 nationwide institutions. A retrospective search of electronic medical records from January 1st, 2009, to December 31st, 2020, was conducted, collecting sociodemographic data, computed tomography images, and pathologic diagnoses. Analysis focused on age, sex, time, location, and geographical region. Comparative assessments were made with global data from a multi-center database. RESULTS: Among 7,765 cases, thymomas (30.7%), benign mediastinal cysts (23.4%), and neurogenic tumors (10.0%) were predominant. Distribution varied across mediastinal compartments, with thymomas (39.6%), benign cysts (28.1%), and neurogenic tumors (51.9%) most prevalent in the prevascular, visceral, and paravertebral mediastinum, respectively. Age-specific variations were notable, with germ cell tumors prominent in patients under 18 and aged 18-29, while thymomas were more common in patients over 30. The composition of mediastinal lesions across different regions of China remained relatively consistent, but it differs from that of the global population. CONCLUSION: This study revealed significant heterogeneity in the spatiotemporal distribution of mediastinal neoplasms. These findings provide useful demographic data when considering the differential diagnosis of mediastinal lesions, and would be beneficial for tailoring disease prevention and control strategies.


Subject(s)
Mediastinal Neoplasms , Humans , Male , Female , Mediastinal Neoplasms/epidemiology , Mediastinal Neoplasms/pathology , Mediastinal Neoplasms/diagnosis , Mediastinal Neoplasms/diagnostic imaging , Adult , Middle Aged , Retrospective Studies , Adolescent , Young Adult , Aged , Child , Spatio-Temporal Analysis , Child, Preschool , Tomography, X-Ray Computed , Incidence
8.
Leukemia ; 38(5): 1107-1114, 2024 May.
Article in English | MEDLINE | ID: mdl-38459167

ABSTRACT

Axicabtagene ciloleucel showed efficacy for relapsed/refractory large B-cell lymphomas (LBCL), including primary mediastinal B-cell lymphomas (PMBCL); however, only few PMBCLs were reported. Aim was to evaluate efficacy and safety of axicabtagene ciloleucel in patients with PMBCL compared to those with other LBCL, enrolled in the Italian prospective observational CART-SIE study. PMBCLs (n = 70) were younger, with higher percentage of bulky and refractory disease, compared to other LBCLs (n = 190). Median follow-up time for infused patients was 12.17 months (IQR 5.53,22.73). The overall (complete + partial) response rate (ORR,CR + PR) after bridging was 41% for PMBCL and 28% for other LBCL, p = 0.0102. Thirty days ORR was 78% (53/68) with 50% (34) CR in PMBCL, and 75% (141/187) with 53% (100) CR in other LBCL, p = 0.5457. Ninety days ORR was 69% (45/65) with 65% (42) CR in PMBCL, and 54% (87/162) with 47% (76) CR in other LBCL; progressive disease was 21% in PMBCL and 45% in other LBCL, p = 0.0336. Twelve months progression-free survival was 62% (95% CI: 51-75) in PMBCL versus 48% (95% CI: 41-57) in other LBCL, p = 0.0386. Twelve months overall survival was 86% (95% CI: 78-95) in PMBCL versus 71% (95% CI: 64-79) in other LBCL, p = 0.0034. All grade cytokine release syndrome was 88% (228/260); all grade neurotoxicity was 34% (88/260), with 6% of fatal events in PMBCL. Non-relapse mortality was 3%. In conclusion, PMBCLs achieved significantly better response and survival rates than other LBCLs.


Subject(s)
Biological Products , Lymphoma, Large B-Cell, Diffuse , Mediastinal Neoplasms , Humans , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/pathology , Lymphoma, Large B-Cell, Diffuse/mortality , Female , Male , Middle Aged , Biological Products/therapeutic use , Mediastinal Neoplasms/pathology , Mediastinal Neoplasms/drug therapy , Mediastinal Neoplasms/mortality , Adult , Prospective Studies , Italy/epidemiology , Aged , Immunotherapy, Adoptive/methods , Follow-Up Studies , Survival Rate , Antigens, CD19 , Treatment Outcome
9.
J Pediatr Hematol Oncol ; 46(3): e248-e250, 2024 Apr 01.
Article in English | MEDLINE | ID: mdl-38446472

ABSTRACT

Germ cell tumors (GCTs) are a heterogeneous group of pediatric cancers. In up to one-third of male patients, a primary mediastinal location is associated with the presence of Klinefelter syndrome (KS). We describe a case of mediastinal GCT in a patient, with unacknowledged KS, that presented a relapse 7 years from diagnosis, that is, 2 years after the end of the follow-up program usually recommended for patients with GCT. There are no recommendations for screening for KS in patients with mediastinal GCT and there are no specific guidelines for surveillance of GCT in KS patients. Our experience suggests that KS should be suspected in patients with mediastinal GCT, and a longer follow-up plan should be implemented when GCT occurs in patients with KS.


Subject(s)
Klinefelter Syndrome , Mediastinal Neoplasms , Neoplasms, Germ Cell and Embryonal , Child , Humans , Male , Klinefelter Syndrome/complications , Klinefelter Syndrome/diagnosis , Neoplasm Recurrence, Local , Mediastinal Neoplasms/complications , Mediastinal Neoplasms/diagnosis , Mediastinal Neoplasms/pathology , Neoplasms, Germ Cell and Embryonal/complications , Neoplasms, Germ Cell and Embryonal/diagnosis , Chronic Disease
10.
Zhonghua Xue Ye Xue Za Zhi ; 45(1): 98-102, 2024 Jan 14.
Article in Chinese | MEDLINE | ID: mdl-38527847

ABSTRACT

Primary mediastinal large B-cell lymphoma (PMBCL) is an aggressive B-cell lymphoma originating from the thymus, which has different clinical and biological characteristics from diffuse large B-cell lymphoma, NOS. PMBCL tends to occur in young women, usually presenting as a large anterior mediastinal mass. Most patients are in stage Ⅰ-Ⅱ at the time of presentation. There is no standard prognostic scoring system for PMBCL. Immunochemotherapy is commonly used in the treatment of PMBCL, but the optimal first-line treatment has not been determined, and the status of radiotherapy is controversial. The value of PET-CT guided therapy needs to be further verified. Relapsed/refractory PMBCL has a poor prognosis, while novel therapies such as PD-1 inhibitors, brentuximab vedotin, and CAR-T can help improve survival in these patients.


Subject(s)
Lymphoma, Large B-Cell, Diffuse , Mediastinal Neoplasms , Adult , Humans , Female , Positron Emission Tomography Computed Tomography , Prognosis , Lymphoma, Large B-Cell, Diffuse/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Immunotherapy , Mediastinal Neoplasms/drug therapy , Mediastinal Neoplasms/pathology
11.
J Cardiothorac Surg ; 19(1): 161, 2024 Mar 28.
Article in English | MEDLINE | ID: mdl-38549142

ABSTRACT

BACKGROUND: Primary cardiac angiosarcomas are very rare and present aggressively with high rates of metastasis. Given the poor prognosis, particularly once disease has spread, early diagnosis and multidisciplinary treatment is essential. CASE PRESENTATION: We present the case of a 46-year-old male who presented with chest pain, intermittent fevers, and dyspnea. Workup with computed tomography scan and transesophageal echocardiography demonstrated a right atrial pseudoaneurysm. Given the concern for rupture, the patient was taken to the operating room, where resection of the pseudoaneurysm and repair using a bovine pericardial patch was performed. Histopathology report initially demonstrated perivascular lymphocyte infiltrate. Six weeks later, the patient represented with chest pain and new word finding difficulty. Workup revealed multiple solid lung, pericardial, brain, and bone nodules. Eventual biopsy of a cardiophrenic nodule demonstrated angiosarcoma, and rereview of the original pathology slides confirmed the diagnosis of primary cardiac angiosarcoma. CONCLUSIONS: Primary cardiac angiosarcomas are often misdiagnosed given the rarity of these tumors, but early diagnosis and initiation of treatment is essential. The unique presentation of our case demonstrates that clinical suspicion for cardiac angiosarcoma should be maintained for spontaneous pseudoaneurysm originating from the right atrium.


Subject(s)
Aneurysm, False , Heart Neoplasms , Hemangiosarcoma , Mediastinal Neoplasms , Thymus Neoplasms , Male , Humans , Animals , Cattle , Middle Aged , Hemangiosarcoma/diagnosis , Hemangiosarcoma/surgery , Delayed Diagnosis , Heart Atria/surgery , Heart Atria/pathology , Heart Neoplasms/diagnosis , Heart Neoplasms/surgery , Heart Neoplasms/pathology , Mediastinal Neoplasms/pathology , Thymus Neoplasms/pathology , Chest Pain
13.
Eur J Surg Oncol ; 50(3): 108019, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38359725

ABSTRACT

BACKGROUND: Mediastinal Yolk sac tumors (YST) are rare and highly malignant extragonadal germ cell tumors with rapid growth and early metastases. We sought to conduct a meta-analysis of published case reports/case series to compare differences in survival, demographics, and treatment modalities between adult and pediatric patients with YST. METHODS: Ovid Embase, Cochrane, and Ovid Medline databases were searched for primary mediastinal pure YST cases. The primary outcome was overall survival (OS). Log-rank and Cox regression were used. This study is registered on PROSPERO (CRD42022367586). RESULTS: Among 846 studies, 87 met our inclusion criteria including 130 patients (Adults: 90 and Pediatrics: 40). About 41.5% of the patients were from the United States. The median age was 23.0 (Q1-Q3: 17.0-30.0), 88.5% were males, and (32.3%) were Asian. Stage II represented almost 40%. AFP was elevated in 96.9%. Respiratory distress was the presenting symptom in 65.4%. Chemotherapy, radiotherapy, and surgery were utilized in 84.6, 23.1, and 64.7% respectively. Median OS was 24 months (Adults: 23 months, Pediatrics: 25 months, P = 0.89). 3- and 5-year OS were 34.4% and 22.9% in adults and 41.5% and 41.5% in pediatrics, respectively. On multivariate analysis, anterior location of tumors, receipt of chemotherapy, and undergoing surgery were associated with better OS. CONCLUSION: Primary mediastinal YSTs are rare, but lethal neoplasms. Our meta-analysis showed that mediastinal YSTs mimic other non-seminomatous mediastinal GCTs in terms of clinical characteristics and available treatment options. Early diagnosis, neoadjuvant chemotherapy, and surgical resection are the key points for effective management and improved outcomes.


Subject(s)
Endodermal Sinus Tumor , Mediastinal Neoplasms , Neoplasms, Germ Cell and Embryonal , Male , Adult , Humans , Child , Young Adult , Female , Endodermal Sinus Tumor/drug therapy , Endodermal Sinus Tumor/pathology , Mediastinal Neoplasms/therapy , Mediastinal Neoplasms/pathology , Mediastinum/pathology , Neoadjuvant Therapy
16.
J Cardiothorac Surg ; 19(1): 28, 2024 Jan 28.
Article in English | MEDLINE | ID: mdl-38281986

ABSTRACT

BACKGROUND: Mediastinal teratoma is an uncommon disease, nevertheless they represent the most common mediastinal germ cell tumors. It may grow silently for several years and remain undiagnosed until the occurrence of a complication. AIM: The main aim of this article is to illustrate the silent evolution of an anterior mediastinal teratoma for over 70 years without presenting any notable complications. CASE PRESENTATION: We present the case of a 70-year-old female, treated for hypertension referred to our department for managing a voluminous mediastinal mass, discovered fortuitously by a general practitioner in a chest X-ray. The anamnesis didn't relate any chest pain, cough, dyspnea nor hemoptysis. The clinical examination, in particular pleuropulmonary, was unremarkable. The workup (Chest X-Ray and CT scan) demonstrated a voluminous pleural mass at the expense of the right mediastinal pleura, rounded in shape, with calcified wall and fluid content. Blood tests did not demonstrate eosinophilia, and hydatid IgG serology was negative. serum human chorionic gonadotropin (hCG) and alpha fetoprotein (AFP) levels were found to be normal. The patient subsequently underwent a right posterolateral thoracotomy with resection of the lesion. The mass was dissected very carefully and then resected in toto. The macroscopic and microscopic histological examination demonstrated a mature cystic teratoma. Surgical resection was an adequate treatment and the prognosis was excellent for the patient. CONCLUSION: Cystic mature teratomas are rare thoracic tumors, often recognized by radiological examination. This article relates the silent evolution that a teratoma could have, and the late appearance of symptoms that it could have.


Subject(s)
Mediastinal Neoplasms , Teratoma , Female , Humans , Aged , Teratoma/diagnosis , Teratoma/surgery , Teratoma/pathology , Mediastinal Neoplasms/diagnosis , Mediastinal Neoplasms/surgery , Mediastinal Neoplasms/pathology , Tomography, X-Ray Computed , Hemoptysis , Thoracotomy
17.
J Thorac Cardiovasc Surg ; 167(2): 488-497.e2, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37330206

ABSTRACT

OBJECTIVE: Pulmonary lymphatic drainage of the lower lobe into the mediastinal lymph nodes includes not only the pathway via the hilar lymph nodes but also the pathway directly into the mediastinum via the pulmonary ligament. This study aimed to determine the association between the distance from the mediastinum to the tumor and the frequency of occult mediastinal nodal metastasis (OMNM) in patients with clinical stage I lower-lobe non-small cell lung cancer (NSCLC). METHODS: Between April 2007 and March 2022, data of patients who underwent anatomical pulmonary resection and mediastinal lymph node dissection for clinical stage I radiological pure-solid lower-lobe NSCLC were retrospectively reviewed. In computed tomography axial sections, the ratio of the distance from the inner edge of the lung to the inner margin of the tumor within the lung width of the affected lung was defined as the inner margin ratio. Patients were divided into 2 groups based on whether the inner margin ratio was ≤0.50 (inner-type) or >0.50 (outer-type), and the association between inner margin ratio status and clinicopathological findings was assessed. RESULTS: In total, 200 patients were enrolled in the study. OMNM frequency was 8.5%. More inner-type than outer-type patients had OMNM (13.2% vs 3.2%; P = .012) and skip N2 metastasis (7.5% vs 1.1%; P = .038). Multivariable analysis revealed that the inner margin ratio was the only independent preoperative predictor of OMNM (odds ratio, 4.72; 95% CI, 1.31-17.07; P = .018). CONCLUSIONS: Tumor distance from the mediastinum was the most important preoperative predictor of OMNM in patients with lower-lobe NSCLC.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Mediastinal Neoplasms , Humans , Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Carcinoma, Non-Small-Cell Lung/surgery , Carcinoma, Non-Small-Cell Lung/pathology , Mediastinum/pathology , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/surgery , Lung Neoplasms/pathology , Retrospective Studies , Neoplasm Staging , Lymphatic Metastasis/pathology , Lung/pathology , Lymph Nodes/diagnostic imaging , Lymph Nodes/surgery , Lymph Nodes/pathology , Lymph Node Excision/methods , Mediastinal Neoplasms/diagnostic imaging , Mediastinal Neoplasms/surgery , Mediastinal Neoplasms/pathology
18.
Am J Clin Oncol ; 47(2): 58-63, 2024 Feb 01.
Article in English | MEDLINE | ID: mdl-37853566

ABSTRACT

BACKGROUND: Studies addressing second hematologic malignancies (SHMs) in patients with primary mediastinal germ cell tumors (PMGCTs) are scarce. To better describe this phenomenon, we analyzed a large case series from a population-based registry. METHODS: The Surveillance, Epidemiology, and End Results database was used to report the clinical characteristics and incidence of SHMs in patients with PMGCT. RESULTS: Among 1297 PMGCTs, 27 cases (2.08%) of SHM were found, with a median latency period of 12 months (95% CI: 5-41). All SHM occurred in males, 20 of whom (74.1%) had a previous nonseminomatous tumor. Acute myeloid leukemia was the most frequent SHM, accounting for 13 cases, 4 of which were acute megakaryoblastic leukemia that occurred within 5 months of diagnosis. The median survival after the diagnosis of SHM was 6 months (95% CI: 2-41). The risk of SHM was significantly higher than expected for the reference population, with a standardized incidence ratio of 6.21 (95% CI: 3.31-10.62) and an absolute excess risk of 19.19 per 10,000 person-years. CONCLUSIONS: Patients with PMGCT are at a higher risk of developing SHMs than the general population, particularly acute myeloid leukemia. This risk ranges from synchronous diagnosis of acute megakaryoblastic leukemia to the later onset of other hematological disorders that might be related to PMGCT therapies. Our findings may help create follow-up schedules for patients with PMGCT and raise the level of suspicion surrounding this association.


Subject(s)
Hematologic Neoplasms , Leukemia, Megakaryoblastic, Acute , Mediastinal Neoplasms , Neoplasms, Germ Cell and Embryonal , Neoplasms, Second Primary , Male , Humans , Hematologic Neoplasms/epidemiology , Neoplasms, Second Primary/epidemiology , Neoplasms, Germ Cell and Embryonal/epidemiology , Neoplasms, Germ Cell and Embryonal/therapy , Mediastinal Neoplasms/epidemiology , Mediastinal Neoplasms/pathology
19.
Histopathology ; 84(1): 238-252, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37771117

ABSTRACT

The mediastinal compartment harbours vital organs and structures, including the heart, great vessels, major airways, and thymus. These structures are embedded in and associated with soft-tissue elements consisting of adipose and fibro-collagenous tissue in which soft-tissue tumours may develop. A detailed inventory of soft-tissue tumours that may be encountered in the mediastinum based on the WHO 2013 classification was published in 2015. In addition, several comprehensive reviews on mediastinal soft-tissue pathology are available, including reviews focusing specifically on a single tumour type. This review will focus on primary neurogenic and spindle cell tumours of the somatic soft tissue of the posterior mediastinum and provide a discussion of the pertinent differential diagnoses.


Subject(s)
Mediastinal Neoplasms , Soft Tissue Neoplasms , Humans , Mediastinum/pathology , Diagnosis, Differential , Soft Tissue Neoplasms/pathology , Mediastinal Neoplasms/diagnosis , Mediastinal Neoplasms/pathology
20.
Histopathology ; 84(1): 183-195, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37988262

ABSTRACT

Mediastinal tumours represent a heterogeneous group of entities derived from the manifold structures located in or adjacent to the mediastinum. Due to the occurrence of some of these tumours in characteristic mediastinal compartments, an anatomical subdivision of the mediastinum in the prevascular (anterior), visceral (middle), and paravertebral (posterior) is helpful for the differential diagnosis. Benign anterior mediastinal tumours linked to an enlargement of the thymic gland mainly consist of thymic cysts and several types of thymic hyperplasia: true thymic hyperplasia, rebound hyperplasia, lymphofollicular hyperplasia, and so-called thymic hyperplasia with lymphoepithelial sialadenitis (LESA)-like features. Mature teratomas, ectopic (para)thyroid tissue, and benign thymic tumours such as thymolipoma or thymofibrolipoma represent further typical tumours of the anterior mediastinum. Pericardial, bronchogenic, or oesophageal duplication cysts predominate in the middle mediastinum, whereas neurogenic tumours and myelolipomas are characteristic findings in the posterior compartment. Vascular tumours, lipomas, adenomatoid tumours, Castleman disease, or mediastinitis are further examples of less frequent tumours or tumorous lesions affecting the mediastinum. This review focuses on benign mediastinal lesions with an emphasis on benign tumours of the thymus. Besides histology, characteristic epidemiological and clinical aspects prerequisite for the correct diagnosis and patient management are discussed.


Subject(s)
Mediastinal Neoplasms , Thymus Hyperplasia , Thymus Neoplasms , Humans , Mediastinum/pathology , Mediastinal Neoplasms/diagnosis , Mediastinal Neoplasms/pathology , Thymus Hyperplasia/diagnosis , Thymus Hyperplasia/pathology , Hyperplasia/pathology , Thymus Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...